LY305

Chemical compound From Wikipedia, the free encyclopedia

LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.[1][2][3]

Legal status
  • Investigational
Quick facts Legal status, Identifiers ...
LY305
Legal status
Legal status
  • Investigational
Identifiers
  • 2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC14H17ClN2O
Molar mass264.75 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1Cl)C#N)N[C@@H]2CCC[C@@]2(C)O
  • InChI=1S/C14H17ClN2O/c1-9-11(6-5-10(8-16)13(9)15)17-12-4-3-7-14(12,2)18/h5-6,12,17-18H,3-4,7H2,1-2H3/t12-,14-/m1/s1
  • Key:CXFSVKGROITHRY-TZMCWYRMSA-N
Close

See also

References

Related Articles

Wikiwand AI